LY6G6D and neoplasm: Endogenous LY6G6D expression on HT55, LS1034, CL-14 and NCI-H508 tumor cells was sufficient to activate Jurkat WT-NFAT luc reporter cells, while no activation was observed in the presence of the LY6G6D negative CRC cell lines SK-CO1 and NCM-460, or in the absence of tumor cells, confirming the selectivity of the LY6G6D/CD3 TcE (Figure 2F).